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Abstract
Background: Novel proteins entering the food chain, for example by genetic modification of
plants, have to be tested for allergenicity. Allermatch™ http://allermatch.org is a webtool for the
efficient and standardized prediction of potential allergenicity of proteins and peptides according to
the current recommendations of the FAO/WHO Expert Consultation, as outlined in the Codex
alimentarius.
Description:  A query amino acid sequence is compared with all known allergenic proteins
retrieved from the protein databases using a sliding window approach. This identifies stretches of
80 amino acids with more than 35% similarity or small identical stretches of at least six amino acids.
The outcome of the analysis is presented in a concise format. The predictive performance of the
FAO/WHO criteria is evaluated by screening sets of allergens and non-allergens against the
Allermatch databases. Besides correct predictions, both methods are shown to generate false
positive and false negative hits and the outcomes should therefore be combined with other
methods of allergenicity assessment, as advised by the FAO/WHO.
Conclusions: Allermatch™ provides an accessible, efficient, and useful webtool for analysis of
potential allergenicity of proteins introduced in genetically modified food prior to market release
that complies with current FAO/WHO guidelines.
Background
The safety of genetically engineered foods must be
assessed before authorities in most nations will consider
granting market approval. An important issue in current
food safety assessment is the evaluation of the potential
allergenicity of food derived from biotechnology. Since
many food allergens are proteins, introduction of a new
("foreign") protein in food by genetic engineering can in
theory cause allergic reactions. Therefore the allergenicity
of novel proteins needs to be assessed. Potential aller-
genicity of a protein is a complex issue and various tests
can be used for prediction, including bioinformatics, in
vitro  digestibility and binding of antisera of allergic
patients. A step-by-step procedure to assess allergenicity is
described by the Codex alimentarius and the FAO/WHO
consultation group [1,2]. An important step in this
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procedure is to use bioinformatics to determine whether
the primary structure (amino acid sequence) of a given
transgenic protein is sufficiently similar to sequences of
known allergenic proteins. The recommended procedure
[1] to establish the possibility of allergenicity is to:
(1) Obtain the amino acids sequences of known allergens
in protein databases in FASTA format (using the amino
acids from the mature proteins only, disregarding the
leader sequences, if any).
(2) Prepare the complete set of 80-amino acid length
sequences derived from the query protein (again disre-
garding the leader sequence, if any).
(3) Compare each of the sequences of (2) with all
sequences of (1), using the program FASTA [3] with
default settings for gap penalty and extension.
According to the Codex alimentarius [2], potential aller-
genicity should be considered, when there is either:
(a) More than 35 % similarity over a window of 80 amino
acids of the query protein with a known allergen.
(b) A stretch of identity of 6 to 8 contiguous amino acids.
This procedure is described in more detail by the expert
consultation and the Codex Alimentarius. Potential aller-
genicity requires further testing of the protein with panels
of patient sera and possibly animal exposure tests [1,2].
Construction and content
Three allergen databases were created, one derived from
SwissProt [4] and one from the WHO-IUIS allergen list
[5]. A third database is a non-redundant combination of
the other two. The databases were created by extracting all
proteins from public databases; SwissProt (version 44.1,
July 5 2004, [4]), PIR [6] and GenPept http://
www.ncbi.nlm.nih.gov. Leader sequences were, if anno-
tated, trimmed from the sequence. The SwissProt allergen
list contains 334 mature protein sequences, while the
WHO-IUIS allergen list (version June 7, 2004) contains
632 sequences (correcting for three internal duplications).
These two databases contain 236 duplicate entries. The
non-redundant combined database contains 730
sequences (Figure 1).
Allermatch™ is build around the FASTA package (version
3.4t21; ftp://ftp.virginia.edu/pub/fasta/, [3]) running
with default parameters (ktup = 2, matrix = Blosum50,
Gap open = -10, Gap extend = -2). The Allermatch™ anal-
ysis tool and the web interface are written in Python and
run on a Suse L Linux Enterprise server with an Apache
web server (version 1.3.26). Allermatch™ provides two
search methods (mode 1 & 2) corresponding with the
FAO/WHO guidelines described above and a third
method (mode 3) is provided as an extra tool. The outline
of the application is schematically presented in Figure 2.
Mode 1: Sliding window approach
The query protein sequence is divided into 80 amino acid
(aa) windows using a sliding window with steps of a sin-
gle residue. Each of these windows is compared with all
sequences in the allergen database of choice. All database
entries showing a similarity higher than a configurable
threshold percentage (default is 35%) to any of the 80 aa
query sequence windows are flagged. Upon completion of
the analysis, a table is shown with all flagged database
entries. Per entry, the highest similarity score is given, as
well as the number of windows having a similarity above
the cut-off percentage. For each allergen database entry
identified, more detailed information on the similarity
between the allergen and query sequence can be retrieved,
such as those areas of both proteins within all 80 aa win-
dows scoring above the cut-off percentage. The similarity
score calculated by FASTA can apply to stretches smaller
than 80 aa, Allermatch™ converts such a similarity score to
an 80 aa window. For example, 40% similarity on a
stretch of 40 aa converts to 20% similarity on an 80 aa
window.
Mode 2: Wordmatch
This method looks for short sub-sequences (words),
which have a perfect identity with a database entry. The
wordsize is configurable (default is 6 aa). The output
given is similar to the output given by Mode 1. All data-
base entries with at least one hit are listed and for each of
these, more detailed information can be retrieved upon
request.
A Venn-diagram showing the relationships of the three data- bases provided by Allermatch™ Figure 1
A Venn-diagram showing the relationships of the 
three databases provided by Allermatch™. This figure 
shows the size and overlap between the SwissProt and 
WHO-IUIS allergen databases.BMC Bioinformatics 2004, 5:133 http://www.biomedcentral.com/1471-2105/5/133
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Mode 3: full FASTA alignment with an Allermatch™ 
allergen database
The Allermatch™ webtool also offers a full alignment of
the query sequence with either of the allergen databases
using FASTA. Although this full alignment is currently not
required by the FAO/WHO guidelines, the full alignment
of protein sequences helps positioning of regions of
potential allergenicity in the whole primary structure of
the protein. The FASTA output is parsed and information
from the allergen database is added and presented.
Utility and discussion
To examine the predictive performance of the FAO/WHO
criteria for potential allergenicity, we have performed two
tests. The first test determines the percentage of false neg-
ative and the second test assesses the amount of false pos-
itives. Both tests are performed with standard settings; for
the sliding window approach an 80 amino acid window
with a 35% similarity cutoff is used and for the word-
match approach 6, 7 and 8 aa word sizes are tested.
The false negative error-rate is estimated by a leave-one-
out method, testing all sequences in each Allermatch™
database against that database with the tested sequence
excluded. Each sequence not resulting in a hit is consid-
ered a false negative. The results of each method/database
combination are summarized in Table 1, column 1. The
results show that the number of false negatives decreases
when a larger database of allergen sequences is used. This
may (partly) be explained by an increased proportion of
similar, but not equal, sequences in the larger databases,
such as isoallergens listed by WHO-IUIS. In examining
the results, various sequences were observed that were not
Table 1: Prediction quality of the FAO/WHO methods.
123
False negatives False negatives (corrected) False positives
Database Method Wordsize Number % Number % Number %
SwissProt Window n.a. 71 / 334 21.3 57 / 320 17.8 3 / 12 25.0
Wordmatch 6 54 / 334 16.2 n.a. n.a. 7 / 12 58.3
7 69 / 334 20.7 n.a. n.a. 6 / 12 50.0
8 78 / 334 23.4 n.a. n.a. 3 / 12 25.0
WHO-IUIS Window n.a. 99 / 632 15.7 78 / 611 12.8 4 / 12 33.3
Wordmatch 6 58 / 632 9.2 n.a. n.a. 9 / 12 75.0
7 98 / 632 15.5 n.a. n.a. 8 / 12 66.7
8 117 / 632 18.5 n.a. n.a. 3 / 12 25.0
SwissProt & 
WHO-IUIS
Window n.a. 101 / 730 13.8 77 / 706 10.9 5 / 12 41.7
Wordmatch 6 55 / 730 7.5 n.a. n.a. 9 / 12 75.0
7 95 / 730 13.0 n.a. n.a. 8 / 12 66.7
8 115 / 730 15.8 n.a. n.a. 3 / 12 25.0
The number and percentage of false negative and false positive results are shown here for all FAO/WHO recommended method/database 
combinations. Result set 1 describes the number of false negatives observed in a leave-one-out approach. The next result set (2) shows the same 
results but corrected for those sequences that were not able to generate a hit against itself due to the short length of the sequence. The last result 
set (3) shows the observed number of false positives when testing 12 non-allergenic sequences with the Allermatch™ webtool. Each of the result 
sets consists of two columns; the first column shows the number of erroneous hits and the total number of sequences in this set. The second 
column shows the percentage of erroneous hits.
Schematic representation of the Allermatch™ webtool Figure 2
Schematic representation of the Allermatch™ webt-
ool. The user submits a protein sequence of interest to the 
Allermatch™ webtool and chooses one of the three align-
ment methods and three databases available. Upon comple-
tion the results are formatted and returned to the user.BMC Bioinformatics 2004, 5:133 http://www.biomedcentral.com/1471-2105/5/133
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able to produce a hit (data not shown) due to their short
length, since a perfect hit on a sequence shorter than 28
amino acids cannot convert to a 35% hit on an 80 amino
acid window. Column 2 of the same table shows the cor-
rected false negative rate after exclusion of these
sequences. Also after this correction the wordmatch with
6 amino acids method shows lower numbers of false neg-
atives than the sliding window approach. It is clear,
however, that in case of short protein sequences the sensi-
tivity of the sliding window methods is reduced.
In the second test, we assess the odds of a false positive by
testing 12 protein sequences known to be non allergenic.
This is based on non-reactivity of these proteins towards
IgE-sera of allergy patients or on the inability to cause IgE-
responses in experimental animals (Table 2). It should be
noted that such data are only available for a limited
number of proteins, which accounts for the size of this
dataset. Each of these 12 sequences was tested against all
databases with all methods. Each non-allergenic sequence
resulting in a hit is considered a false positive (Table 1,
column 3). The number of false positives grows with the
database size, as is to be expected: the chance of a random
hit increases with a larger database. In contrast to the false
negative hit rates the sliding window method gives the
lower error rate. This test might, however, overestimate
the number of false positives. A number of these non-
allergens are related to and display similarities with their
allergenic counterparts, i.e. T1 (related to Bet v 1), human
serum albumin (related to animal serum albumins), and
human heat shock protein 70 (similar to heat shock pro-
teins from fungi and other allergens). A selection of unre-
lated, non-allergenic proteins is therefore likely to give a
lower false positive rate. Caution should be taken in inter-
Table 2: Sequences used for the negative control
Protein Host organism Evidence for non-allergenicity Accession Reference
Amaranth seed albumin Amaranthus hypochondriacus IgG-response, but no raised IgE-levels, after 
administration (intranasal and intraperitoneal) 
of amaranth seed albumin to mice
GenPept 
CAA77664
[14]
T1 Catharanthus roseus No reaction of recombinant T1 in IgE-sera 
binding, basophile histamine release, and skin 
prick testing using patients allergic to the 
related birch pollen allergen Bet v 1
Not applicable [15]
Mite ferritin heavy chain Dermatophagoides 
pteronyssinus
Reaction of mite ferritin with IgG, but not with 
IgE, of sera from patients allergic to house dust 
mite
GenPept 
AAG02250
[16]
Maltose binding protein Escherichia coli No reaction with IgE-sera from patients 
allergic to natural rubber latex (maltose 
binding protein used as part of fusion proteins 
with latex allergens)
SwissProt P02928 [17]
Human serum albumin Homo sapiens No reaction of human serum albumin with IgE-
sera of patients allergic to cat- and porcine-
serum albumin
SwissProt P02768 [18]
Human heat shock protein 70 Homo sapiens No reaction of human heat shock protein 70 
with IgE-sera of patients allergic to heat shock 
protein 70 from Echinococcus granulosus
SwissProt P08107 [19]
Human beta-2-glycoprotein I Homo sapiens Presence of IgM antibodies, but not of IgE 
antibodies, directed against human beta-2-
glycoprotein I in sera from atopic eczema/
dermatitis patients
SwissProt P02749 [20]
Guayule rubber particle protein Parthenium argentatum No cross-reactivity between proteins from 
guayule and latex using IgE-sera from patients 
allergic to latex
Swissprot Q40778 [21]
Purple acid phosphatase 1 Solanum tuberosum Stimulation of IgG-, but no or only low 
stimulation of IgE-antibodies following 
administration of potato acid phosphatase to 
mice (oral and intraperitoneal)
TrEMBL Q6J5M7 [22]
Purple acid phosphatase 2 Solanum tuberosum See above TrEMBL Q6J5M9 [22]
Purple acid phosphatase 3 Solanum tuberosum See above TrEMBL Q6J5M8 [22]
Potato lectin Solanum tuberosum Stimulation of IgG-, but no or only low 
stimulation of IgE-antibodies following 
administration of potato lectin to mice 
(intraperitoneal)
TrEMBL Q9S8M0 [23]BMC Bioinformatics 2004, 5:133 http://www.biomedcentral.com/1471-2105/5/133
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preting these false hit rates. The used methods might per-
form differently with other sets of proteins. For example,
a member of a completely novel group of valid allergens
is likely to generate a false negative result.
The imperfect results show here agree with literature
where the FAO/WHO methods for sequence comparisons
are also shown to lack full predictive capability [7-9].
Interestingly, the results show that there is a balance
between false positives and negatives when increasing the
threshold level for short exact matches from 6 to 8 amino
acids, with the number of false positives sharply decreas-
ing at 8 amino acids (Table 1). The outcomes of these tests
therefore need to be further refined by checking for the
presence of potential IgE-epitopes as recommended by
Kleter and Peijnenburg [7], as well as combined with
results of other assays as recommended by the Codex.
Other methods to decrease false hit rates may also be con-
sidered [8,9]. We plan to implement such supplementary
methods in the future to support the Codex based predic-
tions of potential allergenicity.
The prediction of potential allergenicity by primary
sequence comparison depends on the quality of the data
used for comparison. Addition of a non-allergenic or
poorly annotated protein to any of the Allermatch™ aller-
gen databases would obviously result in undesired false
positives and should be prevented. A workable strategy
could be to use multiple databases, i.e. a database based
on SwissProt's list of allergens, which contains well-anno-
tated sequences from SwissProt, simultaneously with a
larger database based on the WHO-IUIS list, which con-
tains possibly less well annotated sequences from other
protein databases, such as GenPept. For example, a
number of protein accessions in the WHO-IUIS database
do not mention the presence of signal- and/or pro-pep-
tides, where removal of such peptides is essential to pre-
vent false positives. Users of Allermatch™ should, at all
times, take into account the possibility of a false positive
or negative, for example by checking original data (acces-
sions, clinical literature) and confirm results, before arriv-
ing at conclusions. To prevent false positives as much as
possible, one should choose for the well-annotated Swiss-
Prot database. To prevent false negatives, the combination
of the larger WHO-IUIS database with that of SwissProt is
more appropriate. Updates to the SwissProt and WHO-
IUIS allergen lists will be incorporated in the Allermatch™
databases on a regular basis.
Several other websites in the public domain offer
sequence alignment facilities that support the prediction
of potential allergenicity, such as SDAP [10,11], AllerPre-
dict [12] and Farrp [13]. These websites offer search
algorithms that find contiguous similar amino acids
between a query sequence and database sequences (SDAP,
AllerPredict) and more than 35% identity in alignments
(SDAP, AllerPredict), as well as a general FASTA of a query
protein sequence against the database (SDAP, Farrp).
Conclusions
Allermatch™ is an efficient and comprehensive webtool
that combines all bioinformatics approaches required to
assess the allergenicity of protein sequences according to
the current guidelines in the Codex. The application will
be kept up to date with the FAO/WHO criteria and the
SwissProt and WHO-IUIS allergen lists. It will be extended
with other, supplementary methods to support and refine
the prediction of allergenicity.
Availability and requirements
Allermatch™ is platform independent and accessible using
any Netscape 4+ compatible webbrowser at http://aller
match.org.
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